Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4351 Outcomes of lobar and sub-lobar resection for lung neuroendocrine tumours (LNETs, carcinoids) – An ENETS CoE experience

Introduction: LNETs are rare tumours accounting for 1–2% of all lung cancers.

Conference:

Presenting Author:

Authors: Hojerat R, Idaiss I, Aviel G, Korach A, Bel-Ange A,

Keywords: lung neuroendocrine tumour, pulmonary carcinoid, lobar resection, sub-lobar resection, pro-gastrin-releasing peptide,

#4309 Head-to-head comparison of 18F-AIF-NOTA-octreotide and 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine neoplasms

Introduction: 18F-AIF-NOTA-octreotide (F-Oc) is a radiolabelled SSA emerging as a potential alternative to 68Ga-DOTATATE (Ga-DT) due to logistical advantages. Recent studies indicate that F-Oc has comparable diagnostic accuracy to Ga-DT in neuroendocrine neoplasm (NEN) and, in some cases, can identify a greater number of lesions.

Conference:

Presenting Author: Bel-Ange A

Authors: Ben-Haim S, Bel-Ange A, Chicheportichee A, Maimon O, Aburbeh G,

Keywords: 68Ga-DOTATATE, NEN, 18F-AIF-NOTA-octreotide,

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,

#4168 BRCA gene mutations and NEN – Is it just random or a meaningful coincidence?

Introduction: A BRCA mutation denotes a genetic alteration found in either the BRCA1 or BRCA2 genes, both of which function as tumor suppressors. BRCA mutations are widely acknowledged for their link to breast and ovarian cancers, and rarely, to other malignancies such as the pancreas and prostate. Noteworthy, there have been limited reports associating BRCA mutations with NEN, and no possible co-relation to certain racial/ethnic populations has been reported to date.

Conference:

Presenting Author: Bel-Ange A

Authors: Bel-Ange A, Maimon O, Grozinsky-Glasberg S,

Keywords: BRCA gene mutation, NEN-neuroendocrine neoplasm,